



May 26, 2026

To,
The Corporate Relations Department
The BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001.
Ref:- Scrip Code:- 500126

To,
The Listing Department
The National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai - 400051
Ref:- Symbol:- PGHL

Dear Sir / Madam,

Sub: Outcome of the Board Meeting held on May 26, 2026

We are pleased to inform you that a meeting of the Board of Directors of the Company held today (commenced at 02:10 pm and ended at 03:35 pm), the Audited Financial Results for the Financial Year ended March 31, 2026 were approved.

We are enclosing herewith the following:

- a. Audited Financial Results for the Financial Year ended March 31, 2026, as per format prescribed under Regulation 33 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015;
- b. Auditor's Report, in respect of the aforementioned Financial Results, as furnished by the Statutory Auditors of the Company;
- c. A declaration with respect to Audit Report with unmodified opinion to the aforementioned Audited Financial Results

We are pleased to further inform you that the Board of Directors of the Company at its meeting held today, *inter alia*, have recommended a dividend of Rs. 45 per Equity Share (Nominal Value of Rs. 10/- each), for the Financial Year ended March 31, 2026. The dividend shall be paid on or before September 25, 2026, on approval of the Members at the ensuing Annual General Meeting.

Kindly take the same on record.

Thanking you.

For Procter & Gamble Health Limited

Zeal Rupani
Company Secretary

Procter & Gamble Health Limited

CIN: L99999MH1967PLC013726

Registered Office: Ground Floor and First Floor,
P&G Plaza, Cardinal Gracias Road, Chakala,
Andheri-E, Mumbai-400 099 | Tel: (91-22) 6866 9000
www.pghealthindia.com

PROCTER & GAMBLE HEALTH LIMITED

Regd. Office: P&G Plaza, Cardinal Gracias Road, Chakala, Andheri (E), Mumbai : 400 099.
CIN No. L99999MH1967PLC013726, email: investorgrievance.im@pg.com

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND FINANCIAL YEAR ENDED 31ST MARCH 2026

(₹ in lakhs)

Sr. No.	Particulars	(1)	(2)	(3)	(4)	(5)
		Three months ended 31st March 2026 (Audited) (refer note 4)	Preceding Three months ended 31st December 2025 (Unaudited)	Corresponding Three months ended 31st March 2025 (Audited)	Current Year (12 Months) ended 31st March 2026 (Audited) (refer note 3)	Previous Year (Nine Months) ended 31st March 2025 (Audited) (refer note 3)
1.	Revenue from Operations	37 045	37 386	31 099	140 797	93 417
2.	Other Income	400	436	311	1 734	1 035
3.	Total income (1+2)	37 445	37 822	31 410	142 531	94 452
	Expenses					
	a) Cost of materials consumed	8 519	8 447	9 082	30 733	20 059
	b) Purchases of stock-in-trade (Traded goods)	2 231	1 332	1 372	7 058	4 716
	c) Changes in inventories of finished goods,work-in-progress and stock in trade	(1 463)	1 203	(582)	(1 283)	1 475
	d) Employee benefits expenses	5 086	6 181	4 879	22 256	14 206
	e) Depreciation and amortisation expenses	617	590	537	2 359	1 669
	f) Finance costs	21	10	13	55	43
	g) Other expenses	9 113	9 177	8 256	36 367	21 122
4.	Total expenses (4)	24 124	26 940	23 557	97 545	63 290
5.	Profit before tax (3-4)	13 321	10 882	7 853	44 986	31 162
6.	Tax expenses					
	a) Current Tax	2 808	2 926	2 064	11 082	7 763
	b) Deferred Tax Charge / (Credit)	650	(167)	(336)	446	(49)
	c) Adjustment of tax relating to earlier periods	403	364	7	767	7
	Total tax expenses	3 861	3 123	1 735	12 295	7 721
7.	Net Profit for the period / year (5-6)	9 460	7 759	6 118	32 691	23 441
8.	Other Comprehensive Income					
	Items that will not be reclassified to profit or loss					
	i. Re-measurement gains / (losses) on defined benefit plans	(392)	118	(107)	(38)	(350)
	ii. Income tax effect on above	99	(30)	27	10	88
	Other Comprehensive Income, net of tax	(293)	88	(80)	(28)	(262)
9.	Total Comprehensive Income for the period / year (7+8)	9 167	7 847	6 038	32 663	23 179
10.	Paid-up equity share capital (Face Value ₹ 10/- each)	1 660	1 660	1 660	1 660	1 660
11.	Other equity	-	-	-	50 795	52 036
12.	Earnings per equity share (of ₹ 10/- each) *(not annualised)					
	(a) Basic and Diluted (in ₹)	* 56.99	* 46.74	* 36.86	196.94	141.22

PROCTER & GAMBLE HEALTH LIMITED

Regd. Office: P&G Plaza, Cardinal Gracias Road, Chakala, Andheri (E), Mumbai : 400 099.

CIN No. L99999MH1967PLC013726, email: investor@pg.com

Notes:

1. The above audited financial results for the quarter and financial year ended March 31, 2026 have been reviewed by the Audit Committee and taken on record in the meeting of the Board of Directors held on May 26, 2026. These financial results have been subjected to an audit by the statutory auditors of the Company, who have expressed an unmodified opinion thereon. These financial results are prepared and published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement has been prepared in accordance with the Companies ("Indian Accounting Standards") Rules, 2015 ("IND AS") prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
3. The Board of Directors of the Company, on January 23, 2025, approved the change of the Financial Year end from June 30th to March 31st. Accordingly, the previous Financial Year of the Company viz., 2024-25 was for a period of nine months commencing on July 1, 2024, and ending on March 31, 2025. Due to this change of period, the figures of the current period are not comparable with those of the previous year.
4. The figures for the quarter ended March 31, 2026 are the balancing figures between audited figures in respect of financial year ended March 31, 2026 and the limited reviewed year to date figures up to nine months period ended December 31, 2025 of the current Financial Year .
5. The Company has identified Pharmaceuticals as its single primary reportable segment in accordance with the requirement of Ind AS 108 - Operating Segments. Accordingly no separate segment information has been provided.
6. The Board of Directors at its meeting held today, May 26, 2026, have recommended payment of final dividend of ₹ 45 per equity share of ₹ 10 each, aggregating to ₹ 7 470 lakhs. Said final dividend is subject to approval of the shareholders of the Company at the ensuing 59th Annual General Meeting. Accordingly, total dividend for the financial year (including interim dividend and one-time special dividend of ₹ 160 per equity share declared by the Board at its meeting held on February 6, 2026), is ₹ 205 per equity share.
7. The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four labour codes viz the Code on Wages, 2019, the Code on Social Security, 2020, the Industrial Relations Code, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "Labour Codes"). The Labour Codes have been made effective from November 21, 2025. The Ministry of Labour & Employment published Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Company has evaluated the impact of the Labour Codes on the basis of information currently available. Management has assessed that the incremental impact, if any, of these changes are not material given that the current salary structure of the Company is in line with the requirements of the Labour Codes. The Company continues to monitor the finalisation of State Rules and clarifications from the Government on other aspects of the Labour Codes and would make appropriate adjustments, if needed.
8. The Company does not have a subsidiary, an associate or a joint venture as at 31st March, 2026.
9. The audited financial results are available on the website of the Company (www.pghealthindia.com) and on the websites of BSE (www.bseindia.com) and NSE (www.nseindia.com).
10. Previous year's / quarter's figures have been regrouped/ rearranged/reclassified wherever necessary to conform to current period's /quarter's classification.

For and on behalf of the Board of Directors of
Procter & Gamble Health Limited

Milind
Vasant
Thatte

Digitally signed
by Milind Vasant
Thatte
Date: 2026.05.26
15:14:02 +05'30'

Milind Thatte
Managing Director

Place : Mumbai
Date : May 26, 2026

Procter & Gamble Health Limited
Audited Statement of Assets and Liabilities as at March 31, 2026

₹ in Lakhs

Particulars	As at March 31, 2026 (Audited)	As at March 31, 2025 (Audited)
Assets		
Non-current assets		
Property, plant and equipment	9,097	10,463
Capital work-in-progress	1,359	1,096
Investment property	251	437
Right -of -use assets	827	640
Intangible assets	47	71
Financial assets		
(i) Loans	1,223	1,017
(ii) Other financial assets	484	479
Deferred tax assets (Net)	3,070	3,506
Other non-current assets	4,302	291
Non-current tax assets (Net)	7,849	8,781
Total non-current assets	28,509	26,781
Current assets		
Inventories	13,665	10,937
Financial assets		
(i) Trade receivables	16,426	14,540
(ii) Cash and cash equivalents	17,724	18,208
(iii) Bank balances other than (ii) above	805	647
(iv) Loans	209	159
(v) Other financial assets	1,617	1,751
Other current assets	5,024	6,287
Assets held for sale	156	110
Total current assets	55,626	52,639
Total assets	84,135	79,420
Equity and Liabilities		
Equity		
Equity share capital	1,660	1,660
Other equity	50,795	52,036
Total equity	52,455	53,696
Non-current liabilities		
Financial liabilities		
(i) Lease Liabilities	572	481
Provisions	5,470	3,612
Other non-current liabilities	145	100
Total non-current liabilities	6,187	4,193
Current liabilities		
Financial liabilities		
(i) Trade payables		
(a) total outstanding dues of micro and small enterprises	639	1,208
(b) total outstanding dues of creditors other than micro and small enterprises	18,578	15,952
(ii) Lease Liabilities	357	281
(iii) Other financial liabilities	2,125	1,666
Provisions	1,401	697
Current tax liabilities (Net)	877	345
Other current liabilities	1,516	1,382
Total current liabilities	25,493	21,531
Total liabilities	31,680	25,724
Total Equity and Liabilities	84,135	79,420

Procter & Gamble Health Limited

Statement of Cash Flows for the financial year ended March 31, 2026

(₹ in lakhs)

Particulars	Financial Year ended March 31, 2026 (Audited)	Financial Year (nine months) ended March 31, 2025 (Audited)
A. Cash Flows from Operating Activities		
Profit before tax	44 986	31 162
<i>Adjustments for:</i>		
Net unrealised foreign exchange (Gain)/Loss	66	(35)
Allowance for doubtful receivables/ other assets	(368)	59
Provision for Inventory (net of reversals)	297	211
Provision of GST and Rates & Taxes	1 246	158
Depreciation and amortization expense	2 359	1 669
Rental income	(503)	(310)
Provision for employee benefits	(950)	36
Loss on sale of property, plant and equipment	187	13
Share-based payment to employees	188	80
Finance costs	55	43
Interest income	(1 059)	(704)
Operating profit before working capital changes	46 504	32 382
Working capital adjustments:		
(Increase)/Decrease in inventories	(3 025)	(237)
(Increase)/Decrease in trade receivables	(1 481)	(6 031)
(Increase)/Decrease in financial and other Assets	(2 878)	(724)
Increase/(Decrease) in trade payables	1 955	693
Increase/(Decrease) in other liabilities and provisions	3 089	(1 082)
Cash generated from operations	44 164	25 001
Income taxes paid (net)	(10 385)	(8 132)
Net cash flows generated from operating activities (A)	33 779	16 869
B. Cash Flows from Investing Activities		
Purchase and construction of property, plant & equipment, capital work-in-progress	(1 551)	(856)
Proceeds from disposal of property plant & equipment and assets held for sale	118	790
Rental income	503	310
Interest received	1 056	715
Net cash flows generated from investing activities (B)	126	959
C. Cash flow from financing activities		
Dividend paid	(34 028)	(23 240)
Payment of lease liability	(364)	(234)
Net cash flows (used in) financing activities (C)	(34 392)	(23 474)
Net (decrease) in cash and cash equivalents (A+B+C)	(487)	(5 646)
Cash and cash equivalents at the beginning of the year	18 227	23 873
Cash and cash equivalents at the end of the year	17 740	18 227
Components of Cash and Cash equivalents at the end of the year (refer note 14)		
In Current accounts	7 750	9 227
In Term deposits (having original maturity of less than three months)	9 990	9 000
	17 740	18 227

Note:

The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in the Indian Accounting Standard (Ind AS 7) - Statement of Cash Flows.

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of Procter & Gamble Health Limited

Report on the Audit of the Annual Financial Results

Opinion

We have audited the accompanying annual financial results of Procter & Gamble Health Limited (“the Company”) for the year ended March 31, 2026 (“the Statement”), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (‘Listing Regulations’).

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Statement:

(i) is presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and

(ii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards, and other accounting principles generally accepted in India, of net profit and other comprehensive income and other financial information of the Company for the year ended March 31, 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Companies Act, 2013 (“Act”). Our responsibilities under those SAs are further described in the Auditor’s Responsibilities for the Audit of the Annual Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (“ICAI”) together with the ethical requirements that are relevant to our audit of the Statement under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management’s and Board of Directors’ Responsibilities for the Annual Financial Results

The Statement has been prepared on the basis of the annual financial statements. The Company’s Management and the Board of Directors are responsible for the preparation and presentation of this Statement that give a true and fair view of the net profit and other comprehensive income and other financial information of the Company in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and

design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Management and the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Management and the Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made in the Statement by the Management and the Board of Directors.
- Conclude on the appropriateness of the Management and the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the

HARIBHAKTI & CO. LLP

Chartered Accountants

Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The Statement includes the results for the quarter ended March 31, 2026, being the balancing figure between audited figures in respect of the year ended March 31, 2026 and the published unaudited year to date figures up to the nine months period ended December 31, 2025 of the current financial year which were subject to limited review by us.

Our opinion is not modified in respect of this matter.

For Haribhakti & Co. LLP

Chartered Accountants

ICAI Firm Registration No.103523W / W100048

SUMANT
MANGESH
SAKHARDANDE

Digitally signed by
SUMANT MANGESH
SAKHARDANDE
Date: 2026.05.26
15:25:26 +05'30'

Sumant Sakhardande

Partner

Membership No. 034828

UDIN: 26034828JJYHZL9300

Place: Mumbai

Date: May 26, 2026



May 26, 2026

To,
The Corporate Relations Department
The BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001.
Ref:- Scrip Code:- 500126

To,
The Listing Department
The National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400051
Ref:- Symbol:- PGHL

Dear Sir/Madam,

Sub: Declaration with respect to Audit Report with unmodified opinion to the Audited Financial Results for the Financial Year ended March 31, 2026

We hereby declare that Audited Financial Results for the Financial Year ended March 31, 2026 which have been approved by the Board of Directors of the Company at meeting held today, i.e., May 26, 2026, the Statutory Auditors, Haribhakit & Co. LLP have not expressed any modified opinion(s) in their Audit Report.

The above declaration is made pursuant to Regulation 33 (3) (d) of the Securities Exchange and Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Thanking you.

For **Procter & Gamble Health Limited**

Zeal Rupani
Company Secretary

Procter & Gamble Health Limited

CIN: L99999MH1967PLC013726

Registered Office: Ground Floor and First Floor,
P&G Plaza, Cardinal Gracias Road, Chakala,
Andheri-E, Mumbai-400 099 | Tel: (91-22) 6866 9000
www.pghealthindia.com